

1 **Title**

2 **Acaricidal activity of fluralaner against *Ornithodoros moubata* and *Ornithodoros erraticus***
3 **argasid ticks evaluated through *in vitro* feeding.**

4
5 **Authors**

6 Pérez-Sánchez, R.; Oleaga, A.

7
8 **Author's affiliations:**

9 Parasitología Animal, Instituto de Recursos Naturales y Agrobiología de Salamanca (IRNASA,
10 CSIC), Cordel de Merinas, 40-52, 37008 Salamanca, Spain.

11

12 **Author's e-mail address:**

13 ricardo.perez@irnasa.csic.es; ana.oleaga@irnasa.csic.es

14

15 *** Corresponding author:**

16 Ricardo Pérez-Sánchez

17 Parasitología Animal, IRNASA, CSIC,

18 Cordel de Merinas, 40-52, 37008 Salamanca, Spain.

19 Tel.: +34 923219606;

20 fax: +34 923219609.

21 e-mail address: ricardo.perez@irnasa.csic.es

22

23

24 **Abstract**

25 *Ornithodoros erraticus* and *Ornithodoros moubata* are argasid tick vectors that
26 transmit severe diseases such as African swine fever and human relapsing fever. Elimination
27 of the synanthropic populations of these vectors would facilitate the control of these
28 diseases. Fluralaner is a novel isoxazoline that selectively blocks the GABA- and glutamate-
29 gated channels, providing potent insecticidal and acaricidal activity. The aim of the current
30 study was to provide quantitative data on the susceptibility of males, females and third
31 nymphal instar of *O. erraticus* and *O. moubata* to fluralaner through *in vitro* feeding
32 exposure. Fluralaner activity against these developmental stages and species was assessed
33 by feeding the ticks on ovine blood medicated with decreasing fluralaner concentrations
34 between 1 and 10^{-8} $\mu\text{g}/\text{mL}$. Tick mortality was measured at 4, 24 and 48 h and 1, 2 and 3
35 weeks post-feeding. Tests included solvent-treated and untreated blood controls. Fluralaner
36 was extremely active against *O. erraticus*, with mean lethal concentrations 50 (LC₅₀) and 95
37 (LC₉₅) of 2.0×10^{-8} and 5.4×10^{-8} $\mu\text{g}/\text{mL}$, respectively. Fluralaner was also highly active against
38 *O. moubata*, showing a mean LC₅₀ of 1.5×10^{-6} $\mu\text{g}/\text{mL}$ and a mean LC₉₅ of 1.8×10^{-3} $\mu\text{g}/\text{mL}$. In
39 the latter species, the most susceptible life stages were the females (LC₉₅ 1.4×10^{-4} $\mu\text{g}/\text{mL}$).
40 Fluralaner demonstrated potent acaricidal activity against all developmental stages of *O.*
41 *erraticus* and *O. moubata* tested, in the first 48 h after *in vitro* feeding. Therefore, fluralaner
42 has the potential to provide very high acaricidal efficacy to multiple argasid tick species *via*
43 feeding exposure and could be included as an acaricidal agent in integrated programmes for
44 the control of argasid tick vectors and argasid tick-borne diseases.

45

46 **Keywords**

47 *Ornithodoros erraticus*, *Ornithodoros moubata*, argasids, Fluralaner, acaricidal activity.

48

49 1. Introduction

50 Ticks are blood-feeding ectoparasites that transmit a wealth of pathogenic
51 microorganisms that cause severe diseases in livestock, companion animals and people (de
52 la Fuente et al., 2008; Jones et al., 2008).

53 Ticks belong to two main families, the Argasidae (soft ticks) and the Ixodidae (hard
54 ticks), which share a haematophagous lifestyle but display important morphological and
55 biological differences (Sonenshine and Roe, 2014). Most ixodid ticks are non-nidicolous
56 exophiles, which live in open environments such as forests, brush lands, savannahs,
57 meadows and even semi-deserts (Randolf, 2014; Sonenshine and Roe, 2014). Ixodid ticks
58 typically feed over a period of several days (slow feeders) and ingest amounts of blood up to
59 100 times their unfed body weight. Ixodid females feed only once and die after laying several
60 thousands of eggs (Apanaskevich and Olivier, 2014). In contrast, most argasid ticks are
61 nidicolous endophiles, which live in nests, burrows, caves or other shelters used by their
62 hosts or live close by (Gray et al., 2014; Sonenshine and Roe, 2014). Argasid ticks typically
63 complete their blood meal within minutes or hours (fast feeders), ingesting from 5 to 10
64 times their body weight in blood. In addition, adult argasids can feed and reproduce up to 10
65 times, laying several hundreds of eggs *per* trophogonic cycle (Oleaga-Pérez et al., 1990; Vial,
66 2009).

67 Among the argasids, *Ornithodoros erraticus* and *Ornithodoros moubata* have great
68 medical and veterinary importance as vectors of the African swine fever (ASF) virus and of
69 several *Borrelia* spirochetes that cause human relapsing fever (HRF) (Cutler, 2010; Sánchez-
70 Vizcaíno et al., 2015).

71 *O. moubata* is distributed throughout southern and eastern Africa, where it can be
72 found in wild and domestic habitats (Vial, 2009). It feeds on warthogs, domestic swine and
73 humans, and transmits both the ASF virus and the spirochete *Borrelia duttoni*, which is the
74 agent of the East African HRF. In the countries where these diseases are endemic, *O.*
75 *moubata* populations inhabiting anthropic habitats contribute to the persistence of both
76 diseases and, potentially, to their spread to other countries (Cutler, 2010; Sánchez-Vizcaíno
77 et al., 2015; Quembo et al., 2016). *O. erraticus* is the type species of the *O. erraticus*

78 complex, which includes several species distributed throughout the Mediterranean basin,
79 the Middle East, the Caucasus and the Russian Federation (Rebaudet and Parola, 2006; Vial,
80 2009). In southern Europe, *O. erraticus* are found in free-range pig farms, hidden in cracks
81 and fissures inside and around pig-pens, and primarily feeds on swine when it acts as vector
82 for the ASF virus (Oleaga-Pérez et al., 1990; Boinas et al., 2014; Díaz-Martín et al., 2015a;
83 Sánchez-Vizcaíno et al., 2015). Furthermore, species in the *O. erraticus* complex can also
84 feed on humans and transmit several HRF spirochetes such as *B. hispanica* and *B. crocidurae*
85 to them (Diatta et al., 2012; Trape et al., 2013). The presence of *O. erraticus* populations in
86 anthropic environments has contributed to the persistence of ASF and HRF in endemic areas
87 in Eurasia (Pérez-Sánchez et al., 1994; Rebaudet and Parola, 2006; Boinas et al., 2011, 2014).

88 Thus, to be effective, any programme aimed at the prevention and control of ASF and
89 HRF requires the elimination of, at least, the synanthropic populations of these argasid ticks
90 (Díaz-Martín et al., 2015a). However, control of ticks and tick-borne diseases is a difficult
91 task, and none of the methods that have been used hitherto has been found to be fully
92 effective against all ticks and the diseases they transmit.

93 Anti-tick vaccines are a promising, cost-effective and environmentally friendly
94 method for control of tick infestations (de la Fuente et al., 2016), but an effective vaccine
95 against *Ornithodoros* ticks is still lacking (Díaz-Martín et al., 2015a). In addition, the
96 application of acaricides in the habitats colonised by *Ornithodoros* ticks has been ineffective
97 because their nidicolous lifestyle offers shelter from exposure to acaricides (Astigarraga et
98 al., 1995).

99 Consequently, the recent availability of an ectoparasiticide such as fluralaner, which
100 is systemically distributed in the host, instead being applied to the environment, could offer
101 an efficient, alternative method for the control of *Ornithodoros* tick infestations.

102 Fluralaner is a novel, recently developed molecule belonging to the isoxazoline class.
103 It provides potent ectoparasitidal activity by selectively blocking both the GABA- and
104 glutamate-gated channels of arthropod, but not mammalian, neurons (Gassel et al., 2014).
105 The efficacy of fluralaner against fleas and numerous ixodid tick species has already been
106 demonstrated and comprehensively reviewed (Pfister and Armstrong, 2016). More recently,

107 the acaricidal efficacy of fluralaner against several species of mites, including *Sarcoptes*
108 *scabiei* in dogs (Taenzler et al., 2016), *Lynxacarus radovskyi* in cats (Han et al., 2016),
109 *Psoroptes cuniculi* in rabbits (Sheinberg et al., 2017) and *Otodectes cynotis* in dogs and cats
110 (Taenzler et al., 2017), has been also reported.

111 In contrast, information regarding the susceptibility of argasid ticks to fluralaner is
112 scant and only refers to the third nymphal instar (nymphs-3) of *O. moubata* (Gassel et al.,
113 2014; Williams et al., 2015) and *O. turicata* (McTier et al., 2016). Since more information
114 regarding the susceptibility of other developmental stages and species of argasid tick vectors
115 to fluralaner is needed, the current study was designed to provide quantitative data on the
116 susceptibility of male, female and nymphs-3 ticks of *O. erraticus* and *O. moubata* to
117 fluralaner through *in vitro* feeding exposure.

118

119 **2. Material and Methods**

120

121 **2.1. *Ornithodoros erraticus* and *Ornithodoros moubata* ticks**

122 Tick specimens were obtained from laboratory colonies maintained at the Instituto
123 de Recursos Naturales y Agrobiología de Salamanca (IRNASA) (CSIC), Salamanca, Spain. The
124 colony of *O. erraticus* was established from specimens collected in Salamanca, western
125 Spain, and the colony of *O. moubata* was established from specimens submitted from the
126 Institute for Animal Health, Pirbright, Surrey, UK. The ticks were kept in controlled conditions
127 (28 °C, 85% relative humidity (RH) and 12-h photoperiod) and allowed regularly feeding on
128 rabbits. For these experiments, newly moulted unfed males, females and nymphs-3 of *O.*
129 *erraticus* and *O. moubata* were obtained.

130 All animal manipulations were performed according to the rules from the ethical and
131 animal welfare committee of the Institution where the experiments were conducted
132 (IRNASA, CSIC), following the corresponding EU rules and regulations.

133

134 **2.2. Blood preparation**

135 The acaricidal effect of fluralaner on males, females and nymphs-3 of *O. erraticus* and
136 *O. moubata* was assessed through *in vitro* feeding on fresh defibrinated ovine blood. In
137 accordance with previous data obtained by Gassel et al. (2014) and Williams et al. (2015) for
138 *O. moubata* nymphs-3, blood was medicated with the following serially decreasing
139 concentrations of fluralaner: 1, 10^{-2} , 10^{-4} , 10^{-6} and 10^{-8} µg/mL (ppm) (Table 1).

140 Fluralaner was dissolved in dimethyl sulfoxide (DMSO) to produce a stock solution of
141 50 mg/mL, and then diluted in blood to produce a 1,000 µg/mL (1,000 ppm) preparation.
142 This was further diluted in series with ovine blood to obtain the desired test concentrations.

143 Untreated blood and blood treated with 0.002% DMSO were included as controls.
144 This DMSO concentration was the highest concentration to which the ticks were exposed,
145 which was equivalent to the DMSO concentration in the 1 ppm fluralaner preparation.

146

147 **2.3. *In vitro* feeding procedure**

148 For the *in vitro* feeding procedure, a feeding device similar to that described by
149 Kröber and Guerin (2007) was set up (Fig. 1), but substituting the silicone membrane by a
150 Parafilm membrane, in accordance with recommendations of Schwan et al. (1991).

151 The ticks to be fed were counted, weighed and placed into the feeding units, which
152 consisted of plastic vials (26 mm diameter, Deltalab S.L., Barcelona, Spain) with their bottom
153 removed and then sealed with a stretched Parafilm membrane, fixed by means of an elastic
154 band.

155 Ten males, 10 females and 20 nymphs-3 of each species were included per treatment
156 group in each feeding unit, and three repeats per treatment were done (Table 1). Feeding
157 units were set up in six-well plates with 10 ml of blood per well and the plates were
158 incubated at 37 °C with gentle agitation (200 rpm) on a heater-shaker platform. The ticks
159 were allowed to feed to engorgement for a maximum of 2 h (Fig. 1).

160 When the fully engorged ticks detached themselves, they were immediately
161 recovered and transferred to dry filter paper in Petri dishes (one dish per treatment group).
162 Ticks were then weighed and incubated at 28 °C, 85 % RH and a 12-h photoperiod for 4
163 weeks.

164 At 4, 24 and 48 h and 1, 2 and 3 weeks post-feeding, the dishes were examined and
165 numbers of live and dead ticks recorded. Finally, at 4 weeks post-feeding, the moulting rates
166 of the surviving nymphs and the fecundity and fertility rates of the surviving females were
167 also recorded as described by Díaz-Martín et al. (2015b). The whole experiment was
168 performed in triplicate.

169

170 **2.4. Data analysis**

171 The percentage mortality (M) for each tick stage and species in the control and
172 fluralaner-treated groups at every time-point after feeding were calculated using the
173 following formula:

174 $M (\%) = \text{number of dead ticks per treatment} \times 100 / \text{number of fully engorged ticks}$
175 per treatment

176 Corrected mortality percentages were then calculated at each time-point, for each
177 fluralaner concentration, and for each tick stage and species using the Schneider-Orelli's
178 formula (Williams et al., 2015):

179 $\text{Corrected mortality } (\%) = 100 \times (M_F - M_C) / (100 - M_C),$

180

181 where "M_F" was the mortality for each tick stage and species and fluralaner concentration,
182 and "M_C" was the arithmetic mean mortality obtained from all replicates in the
183 corresponding untreated and DMSO-treated blood controls.

184 Corrected mortality percentages were then summarised for each tick stage and for
185 each species, as the arithmetic mean of three replicas at every fluralaner concentration and
186 each time-point post-feeding.

187 Corrected mortality data were then used to calculate the lethal concentrations LC₅₀
188 and LC₉₅, defined as the fluralaner concentrations causing 50% and 95% killing effect at each
189 tick stage and in each species. For this, a Probit regression analysis was performed using the
190 MedCalc® Version 17.2 software.

191 Moulting rates of the nymphs-3 and fecundity and fertility rates of the females were
192 summarised as the mean ± standard deviation of three replicas per fluralaner concentration.

193

194 **3. Results**

195

196 **3.1. Susceptibility of *Ornithodoros erraticus* to fluralaner**

197 All *O. erraticus* males, females and nymphs-3 fed until engorgement in the control
198 and fluralaner-exposed groups, and ingested normal amounts of blood (2.5 mg/male, 7.7
199 mg/female and 1.5 mg/nymph), with no difference between control and fluralaner groups.

200 The mean mortalities obtained from both controls (untreated blood and DMSO-
201 treated blood) were 0% for all the developmental stages between 4 h and 3 weeks post-
202 feeding.

203 The corrected mortality percentages obtained for the fluralaner-treated groups,
204 summarised in table 2. Fluralaner concentrations as low as 10^{-6} ppm caused >95% mortality
205 in the first 24 h post-feeding (hpf) and 100% mortality in 48 hpf.

206 Finally, 10^{-8} ppm of fluralaner caused noticeably lower mortality. With this
207 concentration, cumulative mortalities peaked at 48 hpf and did not further increase between
208 48 hpf and 3 weeks post-feeding.

209 At 4 weeks post-feeding, the surviving nymphs-3 in the 10^{-8} ppm group had moulted
210 normally and showed mean moulting rates of $84.3\% \pm 3.8$, which were similar to moulting
211 rates of the nymphs-3 in the control groups.

212 The surviving females in this group reproduced normally, laying on average 65 ± 13
213 fertile eggs/female, which was within the range of females in the control groups.

214

215 **3.2. Susceptibility of *Ornithodoros moubata* to fluralaner**

216 All the *O. moubata* males, females and nymphs-3 fed until repletion in the control
217 and fluralaner-exposed groups, and ingested normal amounts of blood (30 mg/male, 116
218 mg/female and 21 mg/nymph), without showing differences between control and fluralaner
219 groups.

220 Mortality rates in the untreated blood controls were 0% at 48 hpf, but these slightly
221 increased to 3% in females and to 4.6% in nymphs-3 between 1 and 3 weeks post-feeding

222 (males remained unaffected). In contrast, mortality rates in the DMSO-treated blood
223 controls reached 4.2% in males, 45.5% in females and 33.9% in nymphs-3 in the first 48 hpf,
224 and between 48 hpf and 3 weeks post-feeding no more dead ticks were recorded.
225 Accordingly, mean mortality rates for both control groups were 2.1% for males, 22.8% for
226 females and 15.9% for nymphs-3 at 48 hpf, showing increases between 48 h and 3 weeks
227 post-feeding that were not statistically significant.

228 In the fluralaner-treated groups, 1 ppm of fluralaner caused 100% mortality in the
229 first 4 hpf, while 10^{-2} , 10^{-4} and 10^{-6} ppm caused progressively lower mortality rates, which
230 peaked at 48 hpf (Table 3). These mortality rates did not increase, or increased
231 insignificantly, between 48 h and 3 weeks post-feeding.

232 At 4 weeks post-feeding, surviving ticks in the fluralaner-treated groups moulted and
233 reproduced normally. Moulting rates of the nymphs-3 in the fluralaner groups were on
234 average $90.2\% \pm 1.2$, similar to those of the nymphs-3 in the control groups. Female fertility
235 rates in the fluralaner groups were also similar to those in the control groups (on average,
236 125 ± 22 fertile eggs/female).

237

238 **3.3. Lethal concentrations (LC) for *O. erraticus* and *O. moubata***

239 Table 4 shows LC_{50} and LC_{95} values for fluralaner in males, females and nymphs-3 of
240 both species throughout feeding exposure.

241 For *O. erraticus*, the average LC_{50} was 2.0×10^{-8} $\mu\text{g/mL}$ and the average LC_{95} was $5.4 \times$
242 10^{-8} $\mu\text{g/mL}$. It is notable that both LC_{95} and LC_{50} values were of the same order of magnitude,
243 and that values were similar for the different developmental stages tested, although
244 somewhat lower for nymphs-3, indicating that this was the most susceptible stage.

245 For *O. moubata*, the average LC_{50} value was 1.5×10^{-6} and LC_{95} value 1.8×10^{-3} $\mu\text{g/mL}$,
246 the latter value being up to 3 orders of magnitude higher than the former. In this species,
247 both LCs varied substantially (by one or two orders of magnitude) for all of the
248 developmental stages tested, the lowest values occurring in females.

249

250 **4. Discussion**

251 *In vitro* feeding of soft ticks through artificial membranes, such as silicone and
252 Parafilm, has already been used successfully for the maintenance of *O. coriaceus* and *O.*
253 *moubata* (Osborne and Mellor, 1985; Hokama et al., 1987; Schwan et al., 1991). This method
254 has also been used for studying the effects of ASF virus infection on *O. moubata* and for
255 testing the acaricidal efficacy of fluralaner to *O. moubata* and *O. turicata* nymphs-3 (Rennie
256 et al., 2000; Gassel et al., 2014; Williams et al., 2015; McTier et al., 2016). The method has
257 also been adapted for hard ticks, allowing its application in a variety of research areas,
258 including the testing of novel acaricides, vaccines and antibodies that target tick-protective
259 antigens and the study of tick-pathogen relationships (Kroeber and Guerin, 2007; de la
260 Fuente et al., 2016).

261 In the current study, we have set up an *in vitro* device to feed both *O. moubata* and
262 *O. erraticus* on ovine blood, which is similar to the apparatus formerly used by Kröber and
263 Guerin (2007) to feed hard ticks. Good feeding performance and normal moulting and
264 fertility rates that were recorded for specimens fed on non-medicated blood confirmed the
265 reliability of the method for maintenance of both species, extending its applicability to
266 investigations of *O. erraticus*. As a consequence, the *in vitro* feeding method was applied to
267 an investigation of acaricidal efficacy of fluralaner against adults and nymphs-3 of these two
268 species, in order to confirm and expand on previously reported data for *O. moubata* and to
269 assess the susceptibility of another important argasid vector, *O. erraticus*.

270 The results showed that *O. erraticus* was very susceptible to fluralaner; feeding
271 exposure to doses as low as 10^{-6} µg/mL caused >95% mortality in the first 24 hpf and 100%
272 mortality by 48 hpf. These results prompted us to test an even lower dose of fluralaner (10^{-8}
273 µg/mL), which allowed us to establish an efficacy limit for this species with an average LC₉₅
274 value of 5.4×10^{-8} µg/mL, nymphs-3 representing the most susceptible life stage (LC₉₅ $4.7 \times$
275 10^{-8} µg/mL). This LC₉₅ value was extremely low, approximately 10^6 -fold lower than the
276 lowest LC₉₅ previously reported for any tick species in similar feeding experiments (Gassel et
277 al., 2014; Williams et al., 2015; McTier et al., 2016; Pfister and Armstrong, 2016), indicating
278 that fluralaner can be a very effective agent for control of *O. erraticus*.

279 Regarding *O. moubata*, results of these experiments indicated that this species was
280 also very susceptible to fluralaner, although not as susceptible as *O. erraticus*, since higher
281 fluralaner doses (10^{-2} $\mu\text{g}/\text{mL}$) were required to effectively kill 100% of the *O. moubata*
282 specimens in the same time period (48 h). The mean LC_{95} for *O. moubata* was 1.8×10^{-3}
283 $\mu\text{g}/\text{mL}$, females being the most affected life stage (LC_{95} 1.4×10^{-4} $\mu\text{g}/\text{mL}$).

284 The LC_{95} values obtained here were lower than those previously reported by Williams
285 et al. (2015) for *O. moubata* nymphs-3 after feeding exposure to fluralaner in a similar
286 experiment (LC_{95} 9.104×10^{-2} $\mu\text{g}/\text{mL}$). It is possible that use of different *O. moubata* strains
287 could account for the observed difference in susceptibility to fluralaner. It was also
288 noteworthy that in our experiments *O. moubata* was more affected by use of DMSO as a
289 solvent (15.9% mean mortality in controls) than the *O. moubata* nymphs-3 tested by the
290 former authors (2.5% mean mortality in their equivalent controls). This observation and the
291 fact that *O. erraticus* was unaffected by the DMSO (0% mortality among the specimens fed
292 on DMSO-treated blood) would suggest a particular sensitivity of this *O. moubata* strain to
293 both fluralaner and DMSO. Irrespective of the basis of these differences in *O. moubata*
294 sensitivity to fluralaner, our current results confirm the previous findings of Gassel et al.
295 (2014) and Williams et al. (2015) concerning the high acaricidal effect of fluralaner on the *O.*
296 *moubata* nymphs-3 and provide novel data showing an even greater acaricidal effect against
297 *O. moubata* females. Therefore, these data indicate that fluralaner can be a very efficient
298 acaricidal agent for the control of *O. moubata*.

299 Results of the current study, combined with those obtained by the previously
300 mentioned authors, indicate that fluralaner has the potential to provide very high acaricidal
301 efficacy against multiple argasid tick species via feeding exposure.

302 Finally, it is notable that pharmacokinetic studies in dogs have shown that following
303 single oral administration of 12.5 mg/kg of fluralaner, maximum plasma levels of fluralaner
304 (above 1,000 ng/ml) are on average reached within 24 h. These levels slowly decrease,
305 remaining higher than 10 ng/ml for at least the following 12 weeks (Kilp et al., 2014). This
306 means that, in dogs, plasmatic concentrations of fluralaner would range between 1 ppm and
307 10^{-2} ppm during the first 12 weeks after treatment. Accordingly, the current results suggest

308 that dogs treated in this way would be protected against any hypothetical infestation by *O.*
309 *erraticus* and *O. moubata* during this time period. Currently, fluralaner is not labeled for use
310 in pigs, which are the main hosts to be protected against these two *Ornithodoros* species,
311 and no pharmacokinetic data are as yet available for pigs. As metabolism can be significantly
312 different in pigs compared to dogs, specific data should be obtained for pigs in order to
313 define the acaricidal efficacy of fluralaner in this species. In addition, as pig meat is
314 consumed on a regular basis by many human populations across the world, specific
315 pharmacokinetic data are considered necessary in order to quantify the possible impact on
316 consumer safety of exposure to fluralaner residues.

317

318 **Conclusions**

319 *In vitro* feeding of argasid ticks on blood through Parafilm membranes is a long-
320 established method than can be used for the maintenance of laboratory colonies of soft ticks
321 and for testing novel acaricidal compounds. Fluralaner has demonstrated potent acaricidal
322 efficacy in the first 48 h after *in vitro* feeding exposure against all the tested developmental
323 stages of *O. moubata*, females being most affected. Fluralaner has also demonstrated an
324 even higher acaricidal efficacy against all the developmental stages of *O. erraticus* that were
325 tested, nymphs-3 being the developmental stage most affected. Fluralaner has the potential
326 to provide very high acaricidal efficacy to multiple argasid tick species *via* feeding exposure
327 and it could be included as acaricidal agent in integrated programmes for the control of
328 argasid tick vectors and argasid tick-borne diseases.

329

330 **Authors' contributions**

331 Both authors contributed equally in the study design and protocol, and in monitoring
332 the study, which was carried out in the facilities of IRNASA (CSIC) in Salamanca (Spain). Both
333 authors contributed equally to interpreting the results and in the writing and revision of the
334 manuscript.

335

336 **Funding**

337 MSD Animal Health Innovation GmbH provided the Fluralaner and the costs for this
338 study.

339 The authors declare that there are not conflicts of interest.

340

341 **References**

- 342 Apanaskevich, D.A. and Olivier, J.H.Jr., 2014. Life Cycles and Natural History of Ticks. In:
343 Sonenshine, D.E. y Roe, R.M. (Ed.) *Biology of Ticks*, Vol I. Oxford University Press. pp. 59-
344 73.
- 345 Astigarraga, A., Oleaga-Pérez, A., Pérez-Sánchez, R., Encinas-Grandes, A., 1995. A study of
346 the vaccinal value of various extracts of concealed antigens and salivary gland extracts
347 against *Ornithodoros erraticus* and *Ornithodoros moubata*. *Vet. Parasitol.* 60, 133-147.
- 348 Boinas, F.S., Wilson, A.J., Hutchings, G.H., Martins, C., Dixon L.J., 2011. The persistence of
349 African swine fever virus in field-infected *Ornithodoros erraticus* during the ASF endemic
350 period in Portugal. *PLoS ONE.* 6: e20383. doi:10.1371/journal.pone.0020383.
- 351 Boinas, F., Ribeiro, R., Madeira, S., Palma, M., Lopes de Carvalho, I., Núncio, S., Wilson, A.J.,
352 2014. The medical and veterinary role of *Ornithodoros erraticus* complex ticks (Acari:
353 Ixodida) on the Iberian Peninsula. *J. Vector Ecol.* 39, 238-248.
- 354 Cutler, S.J., 2010. Relapsing fever--a forgotten disease revealed. *J. Appl. Microbiol.* 108,
355 1115-1122.
- 356 de la Fuente, J., Estrada-Pena, A., Venzal, J.M., Kocan, K.M., Sonenshine, D.E., 2008.
357 Overview: Ticks as vectors of pathogens that cause disease in humans and animals.
358 *Front. Biosc.* 13, 6938-6946.
- 359 de la Fuente, J., Kopacek, P., Lew-Tabor, A., Maritz-Olivier, C., 2016. Strategies for new and
360 improved vaccines against ticks and tick-borne diseases. *Parasite Immunol.* 38, 754-769.
- 361 Diatta, G., Souidi, Y., Granjon, L., Arnathau, C., Durand, P., Chauvancy, G., Mane, Y., Sarih, M.,
362 Belghyti, D., Renaud, F., Trape, J.F., 2012. Epidemiology of tick-borne borreliosis in
363 Morocco. *PLoS Neg. Trop. Dis.* 6, e1810. doi:10.1371/journal.pntd.0001810.
- 364 Díaz-Martín, V., Manzano-Román, R., Obolo-Mvoulouga, P., Oleaga, A., Pérez-Sánchez, R.,
365 2015a. Development of vaccines against *Ornithodoros* soft ticks: an update. *Ticks Tick*
366 *Borne Dis.* 6, 211–220.
- 367 Díaz-Martín, V., Manzano-Román, R., Oleaga, A., Pérez-Sánchez, R., 2015b. New salivary anti-
368 haemostatics containing protective epitopes from *Ornithodoros moubata* ticks:
369 Assessment of their individual and combined vaccine efficacy. *Vet. Parasitol.* 212, 336-

370 349.

371 Gassel, M., Wolf, C., Noack, S., Williams, H., Ilg, T., 2014. The novel isoxazoline
372 ectoparasiticide fluralaner: Selective inhibition of arthropod γ -aminobutyric acid- and L-
373 glutamate-gated chloride channels and insecticidal/acaricidal activity. *Insect Biochem.*
374 *Mol Biol.* 45, 111-124.

375 Gray, J.S., Estrada-Peña, A., Vial, L., 2014. Ecology of Nidicolous ticks. In: Sonenshine, D.E. y
376 Roe, R.M. (Ed.) *Biology of Ticks*, Vol II. Oxford University Press. pp. 39.

377 Han, H.S., Noli, C., Cena, T., 2016. Efficacy and duration of action of oral fluralaner and spot-
378 on moxidectin/imidacloprid in cats infested with *Lynxacarus radovskyi*. *Vet. Dermatol.*
379 27, 474–e127. DOI: 10.1111/vde.12390.

380 Hokama, Y., Lane, R.S., Howarth, J.A., 1987. Maintenance of adult and nymphal *Ornithodoros*
381 *coriaceus* (Acari: Argasidae) by artificial feeding through a Parafilm membrane. *J. Med.*
382 *Entomol.* 24, 319–323.

383 Jones, K.E., Patel, N.G., Levy, M.A., Storeygard, A., Balk, D., Gittleman, J.L., Daszak, P., 2008.
384 Global trends in emerging infectious diseases. *Nature* 451, 990-993.

385 Kilp, S., Ramirez, D., Mark, J.A., Roepke, R.K.A., Nuernberger, M.C., 2014. Pharmacokinetics
386 of fluralaner in dogs following a single oral or intravenous administration. *Parasit.*
387 *Vectors* 7, 85. doi:10.1186/1756-3305-7-85.

388 Krobër, T., Guerin, P.M., 2007. *In vitro* feeding assays for hard ticks. *Trends Parasitol.* 23,
389 445-449

390 McTier, T.L. , Chubb, N., Curtis, M.P., Hedges, L., Inskeep, G.A., Knauer, C.S., Menon, S., Mills,
391 B., Pullins, A., Zinser, E., Woods, D.J., Meeus, P., 2016. Discovery of sarolaner: A novel,
392 orally administered, broad-spectrum, isoxazoline ectoparasiticide for dogs. *Vet.*
393 *Parasitol.* 222, 3-11.

394 Oleaga-Pérez, A., Pérez-Sánchez, R., Encinas-Grandes, A., 1990. Distribution and biology of
395 *Ornithodoros erraticus* in parts of Spain affected by African swine fever. *Vet. Rec.* 126,
396 32-37.

397 Osborne, R.W., Mellor, P.S. 1985. Use of a silicone membrane feeding technique in the
398 laboratory maintenance of a colony of *Ornithodoros moubata*. Trop. Anim. Health. Prod.
399 17, 37-38.

400 Pérez-Sánchez, R., Astigarraga, A., Oleaga-Pérez, A., Encinas-Grandes, A., 1994. Relationship
401 between the persistence of African swine fever and the distribution of *Ornithodoros*
402 *erraticus* in the province of Salamanca, Spain. Vet. Rec. 135, 207-209.

403 Pfister, K., Armstrong, R., 2016. Systemically and cutaneously distributed ectoparasiticides: a
404 review of the efficacy against ticks and fleas on dogs. Parasites & Vectors 9, 436-451.

405 Quembo, C.J., Jori, F., Pérez-Sánchez, R., Heath, L., Vosloo, W., 2015. Investigation into the
406 epidemiology of African swine fever virus at the wildlife-domestic interface of the
407 Gorongosa National Park, Central Mozambique. Transbound. Emerg. Dis. 63, 443-451.

408 Randolph, S.E., 2014. Ecology of Non-nidicolous ticks. In: Sonenshine, D.E. y Roe, R.M. (Ed.)
409 Biology of Ticks, Vol II. Oxford University Press. pp. 3-38.

410 Rebaudet, S. and Parola, P., 2006. Epidemiology of relapsing fever borreliosis in Europe.
411 FEMS Immunol. Med. Microbiol. 48, 11-15.

412 Rennie, L., Wilkinson, P.J., Mellor, P.S., 2000. Effects of infection of the tick *Ornithodoros*
413 *moubata* with African swine fever virus. Med. Vet. Entomol. 14, 355-360.

414 Sánchez-Vizcaíno, J.M., Mur, L., Gómez-Villamandos, J.C., Carrasco, L., 2015. An Update on
415 the Epidemiology and Pathology of African swine fever. J. Comp. Pathol. 152, 9-21.

416 Schwan, E.V., Hutton, D., Shields, K.J.B., Townson, S., 1991. Artificial feeding and successful
417 reproduction in *Ornithodoros moubata moubata* (Murray, 1877) (Acarina: Argasidae).
418 Exp. Appl. Acarol. 13, 107-115.

419 Sheinberg, G., Romero, C., Heredia, R., Capulin, M., Yarto, E., Carpio, J., 2017. Use of oral
420 fluralaner for the treatment of *Psoroptes cuniculi* in 15 naturally infested rabbits. Vet
421 Dermatol. doi: 10.1111/vde.12429.

422 Sonenshine, D.E. and Roe, R.M., 2014. Overview: Ticks, People and Animals. In: Sonenshine,
423 D.E. y Roe, R.M. (Ed.) Biology of Ticks, Vol I. Oxford University Press. pp. 3-16.

424 Taenzler, J., Liebenberg, J., Roepke, R.K.A., Frénais, R., Heckerroth, A.R., 2016. Efficacy of
425 fluralaner administered either orally or topically for the treatment of naturally acquired

426 *Sarcoptes scabiei* var. *canis* infestation in dogs. Parasit. Vectors 9, 392. DOI
427 10.1186/s13071-016-1670-7.

428 Taenzler, J., de Vos, C., Roepke, R.K.A., Frénais, R., Heckerroth, A.R., 2017. Efficacy of
429 fluralaner against *Otodectes cynotis* infestations in dogs and cats. Parasit. Vectors 10,
430 30. DOI 10.1186/s13071-016-1954-y.

431 Trape, J.F., Diatta, G., Arnathau, C., Bitam, I., Sarih, M., Belghyti, D., Bouattour, A., Elguero,
432 E., Vial, L., Mane, Y., Balde, C., Prugnolle, F., Chauvancy, G., Mahe, G., Granjon, L.,
433 Duplantier, J.M., Durand, P., Renaud, F., 2013. The epidemiology and geographic
434 distribution of relapsing fever borreliosis in West and North Africa, with a review of the
435 *Ornithodoros erraticus* complex (Acari: Ixodida). PLoS One 8, e78473.

436 Vial, L., 2009. Biological and ecological characteristics of soft ticks (Ixodida: Argasidae) and
437 their impact for predicting tick and associated disease distribution. Parasite 16, 191-202.

438 Williams, H., Zoller, H., Roepke, R.K.A., Zschiesche, E., Heckerroth, A.R., 2015. Fluralaner
439 activity against life stages of ticks using *Rhipicephalus sanguineus* and *Ornithodoros*
440 *moubata* in *in vitro* contract and feeding assays. Parasit. Vectors, 8, 90. DOI
441 10.1186/s13071-015-0704-x.

442

443 **Figure captions.**

444

445 **Figure 1.** Feeding apparatus (A), and engorging *Ornithodoros moubata* females (B) and
446 nymphs-3 (C).

447

448

Table 1. Summary of assays to test the acaricidal efficacy of fluralaner against *Ornithodoros* spp.

Species	Developmental stage	Ticks per treatment group	Number of treatments: untreated blood, blood + DMSO, blood + fluralaner (1, 10 ⁻² , 10 ⁻⁴ , 10 ⁻⁶ , *10 ⁻⁸ ppm)	Replicates	Total tick number
<i>Ornithodoros moubata</i>	female	10	6	3	180
	male	10	6	3	180
	nymph-3	20	6	3	360
<i>Ornithodoros erraticus</i>	female	10	7*	3	210
	male	10	7*	3	210
	nymph-3	20	7*	3	420

* the 10⁻⁸ ppm dilution was tested only with *O. erraticus*.

Table 2. *Ornithodoros erraticus* cumulative corrected mortality in the first 48 h after feeding exposure to fluralaner. Numbers represent the arithmetic mean of 3 replicates per developmental stage (M, males; F, females; N3, nymphs-3) or the arithmetic mean mortality from all the developmental stages tested.

Fluralaner (ppm)	Time post-feeding											
	4 hours				24 hours				*48 hours			
	M	F	N3	All	M	F	N3	All	M	F	N3	All
1	100	100	100	100								
10⁻²	62.9	0	0	21	100	100	100	100				
10⁻⁴	0	0	11.5	3.8	92.6	93.6	100	95.4	100	100	100	100
10⁻⁶	0	0	0	0	91.5	98.0	100	96.5	100	100	100	100
10⁻⁸	0	0	0	0	3.3	2.8	2.7	3.0	9.4	8.2	22.5	13.4

* After 48 hours post-feeding there were no additional mortality and the surviving ticks moulted and reproduced normally.

Table 3. *Ornithodoros moubata* corrected cumulative mortality in the first 48 h after feeding exposure to fluralaner. Numbers represent the arithmetic mean of 3 replicates per developmental stage (M, males; F, females; N3, nymphs-3) or the arithmetic mean mortality from all the developmental stages tested.

Fluralaner (ppm)	Time post-feeding											
	4 hours				24 hours				*48 hours			
	M	F	N3	All	M	F	N3	All	M	F	N3	All
1	100	100	100	100								
10⁻²	0	0	2.4	0.8	49.5	79.3	67.1	65.3	86.9	100	93.9	93.6
10⁻⁴	0	0	0	0	55.1	67.4	82.5	68.3	74.6	84.3	82.5	80.5
10⁻⁶	0	0	0	0	49.0	79.6	62.4	63.7	71.8	80.1	62.4	71.4

*After 48 hours post-feeding, the surviving ticks moulted and reproduced normally. Between 48 hours and 4 weeks post-feeding, the mortality rates did not increase or increased insignificantly.

Table 4. Lethal concentrations (LC) of fluralaner in ppm for males, females and nymphs-3 of *Ornithodoros erraticus* and *Ornithodoros moubata* in the first 48 hours after feeding exposure.

	<i>O. erraticus</i>				<i>O. moubata</i>			
	Males	Females	Nymphs-3	All stages	Males	Females	Nymphs-3	All stages
LC₅₀	2.2×10^{-8}	2.3×10^{-8}	1.6×10^{-8}	2.0×10^{-8}	2.5×10^{-6}	6.5×10^{-7}	2.7×10^{-6}	1.5×10^{-6}
LC₉₅	5.9×10^{-8}	6.1×10^{-8}	4.7×10^{-8}	5.4×10^{-8}	1.8×10^{-2}	1.4×10^{-4}	2.6×10^{-3}	1.8×10^{-3}

Figure 1

Figure 1.

